FI940807A - Peptidejä, joilla on kasvuhormonia vapauttavaa aktiivisuutta - Google Patents

Peptidejä, joilla on kasvuhormonia vapauttavaa aktiivisuutta Download PDF

Info

Publication number
FI940807A
FI940807A FI940807A FI940807A FI940807A FI 940807 A FI940807 A FI 940807A FI 940807 A FI940807 A FI 940807A FI 940807 A FI940807 A FI 940807A FI 940807 A FI940807 A FI 940807A
Authority
FI
Finland
Prior art keywords
peptides
growth hormone
releasing activity
releasing
activity
Prior art date
Application number
FI940807A
Other languages
English (en)
Swedish (sv)
Other versions
FI940807A0 (fi
FI120095B (fi
Inventor
Cyril Y Bowers
David Coy
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of FI940807A0 publication Critical patent/FI940807A0/fi
Publication of FI940807A publication Critical patent/FI940807A/fi
Application granted granted Critical
Publication of FI120095B publication Critical patent/FI120095B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
FI940807A 1991-08-22 1994-02-21 Menetelmä peptidien valmistamiseksi, joilla on kasvuhormonia vapauttavaa aktiivisuutta FI120095B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/748,350 US5663146A (en) 1991-08-22 1991-08-22 Polypeptide analogues having growth hormone releasing activity
US74835091 1991-08-22
US9207026 1992-08-20
PCT/US1992/007026 WO1993004081A1 (en) 1991-08-22 1992-08-20 Peptides having growth hormone releasing activity

Publications (3)

Publication Number Publication Date
FI940807A0 FI940807A0 (fi) 1994-02-21
FI940807A true FI940807A (fi) 1994-02-21
FI120095B FI120095B (fi) 2009-06-30

Family

ID=25009088

Family Applications (2)

Application Number Title Priority Date Filing Date
FI940807A FI120095B (fi) 1991-08-22 1994-02-21 Menetelmä peptidien valmistamiseksi, joilla on kasvuhormonia vapauttavaa aktiivisuutta
FI20050467A FI120691B (fi) 1991-08-22 2005-05-02 Ei-terapeuttinen menetelmä kasvuhormonin vapautumisen edistämiseksi eläimessä

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20050467A FI120691B (fi) 1991-08-22 2005-05-02 Ei-terapeuttinen menetelmä kasvuhormonin vapautumisen edistämiseksi eläimessä

Country Status (26)

Country Link
US (2) US5663146A (fi)
EP (1) EP0605484B1 (fi)
JP (1) JP3179489B2 (fi)
KR (1) KR100247212B1 (fi)
CN (1) CN1035256C (fi)
AT (1) ATE172742T1 (fi)
AU (1) AU666673B2 (fi)
BG (1) BG62655B1 (fi)
BR (2) BR9206398A (fi)
CA (1) CA2116120C (fi)
CZ (1) CZ293281B6 (fi)
DE (1) DE69227462T2 (fi)
DK (1) DK0605484T3 (fi)
ES (1) ES2124263T3 (fi)
FI (2) FI120095B (fi)
HU (1) HU223664B1 (fi)
IL (1) IL102848A (fi)
MX (1) MX9204861A (fi)
NO (1) NO314695B1 (fi)
NZ (1) NZ244034A (fi)
PL (1) PL169562B1 (fi)
RO (1) RO112507B1 (fi)
RU (1) RU2126014C1 (fi)
SK (1) SK282895B6 (fi)
WO (1) WO1993004081A1 (fi)
ZA (1) ZA926337B (fi)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026723A2 (en) 1993-05-14 1994-11-24 Genentech, Inc. ras FARNESYL TRANSFERASE INHIBITORS
AU683121B2 (en) * 1993-12-23 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
SK281963B6 (sk) * 1993-12-23 2001-09-11 Novo Nordisk A/S Zlúčeniny ovplyvňujúce uvoľňovanie rastového hormónu, farmaceutické prostriedky s ich obsahom a ich použitie
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
PL186520B1 (pl) * 1995-06-22 2004-01-30 Novo Nordisk As Związk o właściwościach uwalniania hormonu wzrostu, kompozycja farmaceutyczna zawierająca ten związek i jego zastosowanie
ATE231131T1 (de) * 1996-04-24 2003-02-15 Novo Nordisk As Verbindungen mit wachtumshormon freisetzenden eigenschaften
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1998058950A1 (en) 1997-06-20 1998-12-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
WO1999036431A1 (en) 1998-01-16 1999-07-22 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1999039730A1 (fr) * 1998-02-09 1999-08-12 Kaken Pharmaceutical Co., Ltd. Preparation a administration orale contenant des peptides favorisant la secretion d'hormone de croissance
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
EP1097170A1 (en) 1998-07-13 2001-05-09 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
US6645726B1 (en) 1998-08-10 2003-11-11 Merck & Co., Inc. Canine growth hormone secretagogue receptor
WO2000009537A2 (en) * 1998-08-14 2000-02-24 Administrators Of The Tulane Educational Fund Compounds having growth hormone releasing activity
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US7022677B1 (en) 1999-02-18 2006-04-04 Kaken Pharmaceutical Co., Ltd. Amide derivatives as growth hormone secretagogues
CN1157224C (zh) * 1999-02-18 2004-07-14 科研制药株式会社 用作生长激素促分泌剂的新酰胺衍生物
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
EP1204321B1 (en) 1999-07-26 2005-11-09 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
US20040192593A1 (en) 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
EP1238661A1 (en) * 1999-10-12 2002-09-11 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
JP3498041B2 (ja) * 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
CA2435563A1 (en) 2001-02-02 2002-08-15 Conjuchem Inc. Long lasting growth hormone releasing factor derivatives
US7125840B2 (en) * 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
MXPA04003944A (es) * 2001-10-26 2004-07-08 Baylor College Medicine Una composicion y metodo para alterar la masa corporal fina y propiedades oseas en un sujeto.
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
MY142457A (en) 2001-12-11 2010-11-30 Advisys Inc Plasmid mediated supplementation for treating chronically ill subjects
US7015219B2 (en) 2001-12-19 2006-03-21 Bristol-Myers Squibb Company 3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
MXPA04007638A (es) * 2002-02-07 2004-12-06 Baylor College Medicine Desarrollo modificado de la glandula pituitaria en productos de madres animales prenadas, tratadas con terapia de hormona liberadora de hormona del crecimiento.
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7381730B2 (en) 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US20060167268A1 (en) * 2002-04-09 2006-07-27 Eli Lilly And Company, Patent Division, Growth hormone secretagogues
EP1497317B1 (en) * 2002-04-09 2006-09-06 Eli Lilly And Company Dipeptidic growth hormone secretagogues
US6747048B2 (en) 2002-05-08 2004-06-08 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
AU2003259340A1 (en) 2002-08-23 2004-03-11 Gestion Univalor Societe En Commandite Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US8080682B2 (en) 2006-08-24 2011-12-20 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
WO2004067719A2 (en) * 2003-01-28 2004-08-12 Advisys, Inc. Growth hormone releasing hormone (ghrh) for use in reducing culling in herd animals
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
US7459460B2 (en) 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005016964A2 (en) * 2003-08-04 2005-02-24 Advisys, Inc. Canine specific growth hormone releasing hormone
AU2003272814A1 (en) 2003-10-02 2005-05-19 Ibrahim Al-Habdan Peptide for promoting healing of fractures
EP1711187B1 (en) * 2003-12-31 2010-05-12 VGX Pharmaceuticals, LLC Reducing arthritis and lameness in subjects by growth hormone releasing hormone (ghrh) supplementation
US7517863B2 (en) * 2004-01-20 2009-04-14 Vgx Pharmaceuticals, Inc. Enhanced secretion/retention of growth hormone releasing hormone (GHRH) from muscle cells by species-specific signal peptide
US20050164952A1 (en) * 2004-01-23 2005-07-28 Vital Pharmaceuticals, Inc. Delivery system for growth hormone releasing peptides
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20060025368A1 (en) * 2004-07-23 2006-02-02 Advisys, Inc. Growth hormone releasing hormone enhances vaccination response
US20080261873A1 (en) 2004-08-18 2008-10-23 Elixir Pharmaceuticals, Inc. Growth-Hormone Secretagogues
WO2006116401A1 (en) 2005-04-28 2006-11-02 Bristol-Myers Squibb Company C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
DK2425715T3 (da) 2005-08-31 2014-04-28 Univ Tennessee Res Foundation Behandling af symptomer på nyresygdom med selektive, androgenreceptor modulatorer (SARM)
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
WO2008006019A2 (en) * 2006-07-06 2008-01-10 Advisys Inc. Growth hormone releasing hormone treatment to decrease cholesterol levels
MX2009000385A (es) 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
HUE026571T2 (hu) 2006-08-02 2016-06-28 Cytokinetics Inc Adott kémiai anyagok, készítmények és imidazopiridineket magukba foglaló eljárások
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
US20100099640A1 (en) 2007-05-04 2010-04-22 Joannes Geuns Tissue degeneration protection
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
PT2872482T (pt) 2012-07-13 2020-09-22 Oncternal Therapeutics Inc Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm)
KR20150070180A (ko) 2012-10-24 2015-06-24 다이이찌 산쿄 가부시키가이샤 근위축성 측삭 경화증 치료제
EP4140497A1 (en) 2013-04-08 2023-03-01 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
BR112021025659A2 (pt) 2019-06-27 2022-02-08 Cytokinetics Inc Polimorfo, composição, métodos para preparar o polimorfo e para tratar uma doença associada com disfunção neuromuscular ou não neuromuscular, fraqueza muscular e/ou fadiga muscular, e, kit
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224316A (en) * 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
CA1175810A (en) * 1979-03-30 1984-10-09 Frank A. Momany Synthetic peptides having pituitary growth hormone releasing activity
US4228157A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228155A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) * 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223021A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
BR8208035A (pt) * 1981-12-28 1983-11-22 Beckman Instruments Inc Peptideos sinteticos tendo atividade liberadora de hormonio do crescimento da pituitaria
US4410513A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
US4839344A (en) * 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US4880777A (en) * 1987-09-01 1989-11-14 Eastman Kodak Company Synthetic peptides having growth hormone releasing activity
ATE113607T1 (de) * 1988-01-28 1994-11-15 Polygen Holding Corp Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität.
WO1989007110A1 (en) * 1988-01-28 1989-08-10 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
AU633003B2 (en) * 1988-05-11 1993-01-21 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
EP0540626A1 (en) 1990-07-24 1993-05-12 Eastman Chemical Company Process for synthesizing peptides
US5486505A (en) * 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
RU2126014C1 (ru) 1999-02-10
AU2541692A (en) 1993-03-16
KR100247212B1 (ko) 2000-03-15
ES2124263T3 (es) 1999-02-01
FI940807A0 (fi) 1994-02-21
IL102848A0 (en) 1993-01-31
HUT69178A (en) 1995-08-28
BR1100309A (pt) 2000-08-01
CN1035256C (zh) 1997-06-25
NO940592D0 (no) 1994-02-21
CA2116120C (en) 2002-12-03
HU223664B1 (hu) 2004-11-29
EP0605484B1 (en) 1998-10-28
BG98489A (bg) 1995-02-28
RO112507B1 (ro) 1997-10-30
CA2116120A1 (en) 1993-02-23
ZA926337B (en) 1993-04-22
HU9400495D0 (en) 1994-05-30
BG62655B1 (bg) 2000-04-28
WO1993004081A1 (en) 1993-03-04
EP0605484A1 (en) 1994-07-13
FI20050467A (fi) 2005-05-02
DE69227462D1 (de) 1998-12-03
CZ40094A3 (en) 1994-11-16
ATE172742T1 (de) 1998-11-15
US5663146A (en) 1997-09-02
FI120095B (fi) 2009-06-30
JP3179489B2 (ja) 2001-06-25
JPH07507039A (ja) 1995-08-03
DE69227462T2 (de) 1999-04-08
SK282895B6 (sk) 2003-01-09
MX9204861A (es) 1994-06-30
BR9206398A (pt) 1994-12-27
CN1073684A (zh) 1993-06-30
NO940592L (no) 1994-04-14
NZ244034A (en) 1995-08-28
AU666673B2 (en) 1996-02-22
US5776901A (en) 1998-07-07
SK20494A3 (en) 1994-10-05
CZ293281B6 (cs) 2004-03-17
NO314695B1 (no) 2003-05-05
IL102848A (en) 1998-04-05
DK0605484T3 (da) 1999-07-05
FI120691B (fi) 2010-01-29
PL169562B1 (pl) 1996-08-30

Similar Documents

Publication Publication Date Title
FI940807A (fi) Peptidejä, joilla on kasvuhormonia vapauttavaa aktiivisuutta
NO884408L (no) Kontrollerte frigjoeringsformuleringer av tetracyklinforbindelser.
RS20090086A (en) Nucleoside analogs with carobxamidine modified monocyclic base
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
MX163592B (es) Compuestos de polipeptido que tienen actividad liberadora de la hormona del crecimiento
NO165237C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzensulfonamido-indanylforbindelser.
LV11985A (lv) Noteiktu cistina atvasinajumu farmakologiska izmantosana
FI930261A0 (fi) Polypeptidfoereningar som har vaexthormon frigoerande verkan
NO165916C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive, ikke-aromatiske fluorallylamin mao-inhibitorer.
IT1149234B (it) Procedimento per la preparazione di peptidi aciclici aventi attivita' terapeutica
NO167144C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv imidazo (4,5-f) isokinolin-2-on.
NO167381C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv (e)-2-(p-fluorfenethyl)-3-fluorallylamin.
SU1549026A1 (ru) 4-Карбэтокси-4-(2-п-толиламинотиазолил-4)-гексановая кислота, проявляющая противовоспалительную активность
SU1578880A1 (ru) Пептид, обладающий защитным действием против вируса ящура штамма a
NO871195L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv 1-cyklopropyl-6-fluor-1,4-dihydro-4-okso-7-piperazino kinolin-3-karboksylsyre.
NO912745L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,2,5,6-tetrahydropyridinforbindelser.
NO164479C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive peptidforbindelser.
SU1363769A1 (ru) Метиловый эфир 4-дифенилметилиденгидразино-2-оксо-4-фенил-3-бутеновой кислоты, проявляющий противовоспалительную активность
NO912746L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinuklidinforbindelser.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120095

Country of ref document: FI

MM Patent lapsed